GLOW is a research-grade peptide blend of GHK-Cu, BPC-157, and TB-500, and people run it mainly for skin rejuvenation and cosmetic improvement, with a strong secondary use for wound healing and scar reduction. The most common community dose is 10 milligrams daily across a reported range of 1 to 50 milligrams, generally taken daily. Nausea and other GI upset occasionally surfaces in user reports, but it is not a consistent theme. The honest caveat: there is no FDA-approved use for the blend or its components, so every application is off-label or compounded, and the human evidence is preclinical and animal-only.
Data last updated
Measured on 5 of 6 axes
Evidence shape
GLOW currently holds a low evidence tier, supported by nine published human studies focused on treatment and diagnostic applications. While these studies provide exploratory data, the research lacks the rigor of registered clinical trials, and no completed trials exist to validate its efficacy or safety profile. The current body of evidence is limited to thin, single-trial findings and preclinical research, leaving the peptide without the large-scale, blinded data necessary to establish a clear clinical standard.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
8 studies
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How GLOW is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Eight published human studies are on record for this tier, but none yielded a reliably captured dose, frequency, or cycle.
No structured protocol details captured for this tier yet.
Of eight community reports, three dosed daily at 2–5 mg subQ and one every other day at 1 mg; the remaining four reported doses around 9–10 mg without stating a schedule.